BridgeBio Oncology Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that BridgeBio Oncology Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($44.76M) | Nov 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($28.44M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | $918.3K | Aug 1, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($22.06M) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($487.4K) | Aug 1, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($487.4K) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($17.32M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | $2.21M | Aug 1, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($21.82M) | Nov 12, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($15.44M) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | $1.10M | Aug 1, 2025 |
| Q1 | 2025 | Mar 31, 2024 | $1.10M | May 15, 2025 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($49.18M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.12M) | Aug 1, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.42M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($19.66M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($152.3K) | Aug 1, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($66.7K) | May 15, 2025 |